Efficacy of ifosfamide combined with liposome doxorubicin on osteosarcoma and its effects on serum IL-10, TNF-alpha, and IFN-gamma in patients with osteosarcoma

Objective: To evaluate the effects of ifosfamide combined with liposome doxorubicin on osteosarcoma (OS) and its effects on serum IL-10, TNF-alpha, and IFN-gamma in patients with OS. Methods: A total of 86 patients with OS who received chemotherapy in Honghui Hospital, Xi'an Jiaotong University from Jan. 2017 to Dec. 2019 were enrolled. Patients treated by conventional doxorubicin + ifosfamide were assigned to the regular group (n=40). Others treated by liposome doxorubicin + ifosfamide were assigned to the research group (n=46). The clinical efficacy, 2-year survival rate, and adverse reactions of the two groups were evaluated and compared. ELISA was adopted for quantification of tumor specific growth factor (TSGF), vascular endothelial growth factor (VEGF), erb-b2 receptor tyrosine kinase 3 (ERBB3), tumor necrosis factor-alpha (TNF-alpha), interferon-gamma-gamma (IFN-gamma), and interleukin-10 The EORTC Quality of Life Questionnaire (QLQ-C30) was adopted to evaluate a patient's life quality. Results: The research group showed a higher total effective rate and a higher 2-year survival rate than the regular group, but lower incidences of liver and kidney function injury, thrombocytopenia, and cardiotoxicity than the regular group. After therapy, lower levels of serum TSGF, VEGF, ERBB3, and TNF-alpha were found in the research group than those in the regular group. Higher levels of IFN-gamma and IL-10 were found in the former than those in the latter. The research group got higher scores of QLQ-C30 than the regular group. Conclusion: Liposome doxorubicin + ifosfamide can improve the clinical efficacy on patients with OS and improve their recovery and life quality.